Donidalorsen for children with hereditary angioedema
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study tests a new medicine, donidalorsen, to prevent swelling attacks in children ages 2 to 11 with hereditary angioedema (HAE). If your child has HAE type 1 or 2, this trial may help find a treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 2 and 11 years old.
- Your child must weigh at least 20 pounds (9 kg).
- Your child must have a confirmed diagnosis of HAE type 1 or 2, based on blood tests or genetic testing.
- Your child should not have other types of angioedema (like HAE with normal C1 inhibitor).
- Your child cannot have taken other investigational drugs in the past month before screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study tests a long-term daily pill to prevent swelling attacks in people with hereditary angioedema (HAE). The pill, called deucrictibant, is designed to block a protein involved in causing attacks. It's for adolescents and adults who want to reduce how often swelling episodes occur.
This trial tests an oral medication called deucrictibant to prevent and treat swelling attacks in people with hereditary angioedema. It may help reduce the number and severity of attacks.
This study is for people who already finished a previous trial of the drug ADX-324 for hereditary angioedema. It tests the long-term safety and effectiveness of continuing the medication.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
This trial tests an experimental medication called sebetralstat for treating angioedema attacks in children with hereditary angioedema (HAE). If your child is between 2 and 11 years old and has HAE, they may be able to join.
Hear when a new Hereditary Angioedema (HAE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.